Circular RNA (Ribonucleic Acid) composition for coding neuraminidase and application of circular RNA composition in preparation of anti-influenza virus product

Delivering neuraminidase subtypes of different influenza virus strains through circular RNA vaccine technology, solving the problem of narrow protection spectrum of existing influenza vaccines and achieving broad-spectrum protection and efficient immune response to influenza viruses.

CN118903400APending Publication Date: 2024-11-08SUN YAT SEN UNIVERSITY SHENZHEN +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410899915.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-05
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing influenza vaccine has poor protection effect on the new influenza virus, making it difficult to cope with the virus's antigen drift and antigen transformation, and the main antigen component is hemagglutinin, which makes it difficult to induce an immune response to neuraminidase, resulting in a narrow protection spectrum.

Method used

The circular RNA vaccine was prepared by using circular RNA to deliver neuraminidase subtypes (N1, N2 and BV) from different influenza virus strains as antigens, inducing strong NA antibody and T cell responses, achieving homologous and Broad-spectrum protection of heterologous strains.

Benefits of technology

It has achieved broad-spectrum protection of influenza viruses, induced a high-level and broad-spectrum immune response, provided a new vaccination strategy for responding to seasonal influenza, and improved the adaptability and protection effect of the vaccine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903400A_ABST
    Figure CN118903400A_ABST
Patent Text Reader

Abstract

The invention discloses a circular RNA (Ribonucleic Acid) composition for coding neuraminidase and application of the circular RNA composition in preparation of an anti-influenza virus product, the neuraminidase comprises three subtypes, namely N1, N2 and BV; the circular RNA composition contains circular RNA1-circular RNA3, and each of the circular RNA1-circular RNA3 contains a nucleic acid molecule that encodes the N1, a nucleic acid molecule that encodes the N2, and a nucleic acid molecule that encodes the BV. Neuraminidase of three influenza virus strains is delivered through circular RNA, and the prepared trivalent vaccine can induce an organism to generate strong NA antibody and T cell response, has broad-spectrum protective efficacy on homologous and heterologous strains, induces high-level and broad-spectrum immune response, and provides a new inoculation strategy for coping with seasonal influenza.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a circular RNA composition encoding neuraminidase and an application thereof in preparing an anti-influenza virus product. Background Art

[0002] Influenza viruses are highly variable, and antigenic drift and antigenic shift will produce new strains, causing them to spread widely in different seasons, years and regions, posing a serious threat to human health. Seasonal influenza is divided into two lineages: H1N1, H3N2 and influenza B. Existing influenza vaccines generally have poor adaptability and are difficult to effectively prevent infections caused by new strains. Therefore, effective protection can usually only be achieved by inoculating influenza vaccines against the strains prevalent in the season.

[0003] The main antigen component of the existing influenza vaccine on the market is hemagglutinin (HA), which is easy to mutate as the target, mainly inducing an immune response to HA, and it is difficult to produce an immune response to the more conservative neuraminidase (NA), and the protection spectrum is narrow. When the virus HA mutates (antigenic drift or antigenic shift), this type of vaccine will become ineffective. The seasonal influenza vaccines currently on the market are mainly based on traditional trivalent / quadrivalent inactivated vaccines, recombinant protein vaccines and attenuated virus vaccines, while new vaccines such as vaccines based on protein nanoparticles and mRNA vaccines are rare. Circular RNA (circRNA) is a special class of RNA molecules with a closed circular structure, which is not affected by RNA exonucleases, has more stable expression, is not easy to degrade, and has a wide range of application potential in the field of vaccine research and development. Prior art CN112126647A discloses a circular RNA vaccine for influenza virus, but does not include influenza B, and the protective effect of the vaccine is poor when used at low doses. Therefore, it is urgent to develop a safer, more efficient and more adaptable influenza vaccine. Summary of the invention

[0004] In order to solve the above problems existing in the prior art, the present invention provides a circular RNA composition encoding neuraminidase and its application in preparing an anti-influenza virus product.

[0005] The first object of the present invention is to provide a circular RNA composition encoding neuraminidase.

[0006] The second object of the present invention is to provide the use of the circular RNA composition in the preparation of anti-influenza virus products.

[0007] The third object of the present invention is to provide an antigen for preparing influenza virus vaccine.

[0008] The fourth object of the present invention is to provide the use of the antigen in preparing influenza virus vaccines.

[0009] A fifth object of the present invention is to provide an influenza virus vaccine.

[0010] In order to achieve the above object, the present invention is implemented by the following scheme:

[0011] The present invention mainly prepares a circular RNA vaccine by delivering three neuraminidase (NA) subtypes from strains A / Michigan / 45 / 2015 (H1N1), A / Switzerland / 9715293 / 2013 (H3N2) and B / Flordia / 12 / 2017 as antigens through circular RNA (circRNA), successfully induced strong NA antibody and T cell responses in a mouse model, and demonstrated broad-spectrum protective efficacy against homologous and heterologous strains.

[0012] The present invention requests protection for the following contents:

[0013] A circular RNA composition encoding neuraminidase, wherein the neuraminidase includes three subtypes, namely N1, N2 and BV; wherein the amino acid sequence SEQ ID NO.1 of N1 has at least 95% consistency, the amino acid sequence SEQ ID NO.3 of N2 has at least 95% consistency, and the amino acid sequence SEQ ID NO.5 of BV has at least 95% consistency; the circular RNA composition comprises circular RNA1 to circular RNA3, and the circular RNA1 to circular RNA3 respectively comprise a nucleic acid molecule encoding the N1, a nucleic acid molecule encoding the N2 and a nucleic acid molecule encoding the BV.

[0014] N1 is the neuraminidase subtype from influenza A (H1N1) virus strain A / Michigan / 45 / 2015 (H1N1), N2 is the neuraminidase subtype from influenza A subtype virus strain A / Switzerland / 9715293 / 2013 (H3N2), and BV is the neuraminidase subtype from influenza B subtype virus strain B / Florida / 12 / 2017 (Victoria).

[0015] Preferably, the amino acid sequence of N1 is shown as SEQ ID NO.1, the amino acid sequence of N2 is shown as SEQ ID NO.3, and the amino acid sequence of BV is shown as SEQ ID NO.5.

[0016] Preferably, the nucleotide sequence of the nucleic acid molecule encoding the N1 is as shown in SEQ ID NO.2 or as shown in the completely complementary sequence shown in SEQ ID NO:2.

[0017] Preferably, the nucleotide sequence of the nucleic acid molecule encoding the N2 is as shown in SEQ ID NO.3 or as shown in the completely complementary sequence as shown in SEQ ID NO:4.

[0018] Preferably, the nucleotide sequence of the nucleic acid molecule encoding the BV is as shown in SEQ ID NO.5 or the completely complementary sequence as shown in SEQ ID NO:6.

[0019] Preferably, the expression vectors of circular RNA1 to circular RNA3 use PUC57-T4-PIE vector as the backbone vector.

[0020] More preferably, an expression cassette is connected between the T7 promoter and the EcoRV restriction site of the PUC57-T4 vector, and the expression cassette comprises 3'Intron, E2, SPACER 2, IRES, NA molecule, SPACER 1, E1 and 5'Intron connected in sequence from 5'→3' direction, and the NA molecule is a nucleic acid molecule encoding the N1, a nucleic acid molecule encoding the N2 or a nucleic acid molecule encoding the BV.

[0021] The use of any of the circular RNA compositions in the preparation of anti-influenza virus products should also be within the protection scope of the present invention.

[0022] An antigen for preparing an influenza virus vaccine comprises a circular RNA composition encoding neuraminidase, wherein the neuraminidase comprises three subtypes, namely N1, N2 and BV; wherein the amino acid sequence SEQ ID NO.1 of N1 has at least 95% consistency, the amino acid sequence SEQ ID NO.3 of N2 has at least 95% consistency, and the amino acid sequence SEQ ID NO.5 of BV has at least 95% consistency; the circular RNA composition comprises circular RNA1 to circular RNA3, wherein the circular RNA1 to circular RNA3 respectively comprise a nucleic acid molecule encoding the N1, a nucleic acid molecule encoding the N2 and a nucleic acid molecule encoding the BV.

[0023] Preferably, the amino acid sequence of N1 is shown as SEQ ID NO.1, the amino acid sequence of N2 is shown as SEQ ID NO.3, and the amino acid sequence of BV is shown as SEQ ID NO.5.

[0024] Preferably, the nucleotide sequence of the nucleic acid molecule encoding the N1 is as shown in SEQ ID NO.2 or as shown in the completely complementary sequence shown in SEQ ID NO:2.

[0025] Preferably, the nucleotide sequence of the nucleic acid molecule encoding the N2 is as shown in SEQ ID NO.4 or as shown in the completely complementary sequence shown in SEQ ID NO:4.

[0026] Preferably, the nucleotide sequence of the nucleic acid molecule encoding the BV is as shown in SEQ ID NO.6 or the completely complementary sequence as shown in SEQ ID NO:6.

[0027] Preferably, in the antigen, the mass ratio of circular RNA1, circular RNA2 and circular RNA3 is (1-2): (1-2): (1-2).

[0028] More preferably, in the antigen, the mass ratio of circular RNA1, circular RNA2 and circular RNA3 is 1:1:1.

[0029] Preferably, the expression vectors of circular RNA1 to circular RNA3 use the PUC57-T4 vector as a backbone vector.

[0030] More preferably, an expression cassette is connected between the T7 promoter and the EcoRV restriction site of the PUC57-T4 vector, and the expression cassette comprises 3'Intron, E2, SPACER 2, IRES, NA molecule, SPACER 1, E1 and 5'Intron connected in sequence from 5'→3' direction, and the NA molecule is a nucleic acid molecule encoding the N1, a nucleic acid molecule encoding the N2 or a nucleic acid molecule encoding the BV.

[0031] Preferably, the antigen further comprises a drug delivery carrier. The drug delivery carrier includes but is not limited to cationic polymers, extracellular vesicles and lipid nanoparticles.

[0032] More preferably, the drug delivery vehicle comprises lipid nanoparticles.

[0033] Further preferably, the circular RNA composition is loaded into the lipid nanoparticles by microfluidics technology.

[0034] Further preferably, the lipid nanoparticles are obtained by fully reacting ionizable cationic lipids, cholesterol, distearoylphosphatidylcholine and 1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol 2000.

[0035] More preferably, the molar ratio of the ionizable cationic lipid, cholesterol, distearoylphosphatidylcholine and 1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol 2000 is (48-52):(8-12):(35-40):(1-2).

[0036] Still further preferably, the molar ratio of the ionizable cationic lipid, cholesterol, distearoylphosphatidylcholine and 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000 is 50:10:37.5:1.5.

[0037] More preferably, the encapsulation efficiency of the lipid nanoparticles for the circular RNA composition is 90% to 100%.

[0038] Still more preferably, the encapsulation rates of the lipid nanoparticles for the circular RNA1, circular RNA2 and circular RNA3 are 93% to 95%, 93% to 95% and 93% to 95%, respectively.

[0039] Most preferably, the encapsulation efficiency of the lipid nanoparticles for the circular RNA1, circular RNA2 and circular RNA3 is 93.52%, 94.65% and 93.74%, respectively.

[0040] The use of any of the antigens in the preparation of influenza virus vaccines should also be within the scope of protection of the present invention.

[0041] An influenza virus vaccine comprises an antigen, wherein the antigen comprises a circular RNA composition encoding neuraminidase, wherein the neuraminidase comprises three subtypes, namely N1, N2 and BV; wherein the amino acid sequence SEQ ID NO.1 of N1 has at least 95% consistency, the amino acid sequence SEQ ID NO.3 of N2 has at least 95% consistency, and the amino acid sequence SEQ ID NO.5 of BV has at least 95% consistency; the circular RNA composition comprises circular RNA1 to circular RNA3, wherein the circular RNA1 to circular RNA3 respectively comprise a nucleic acid molecule encoding the N1, a nucleic acid molecule encoding the N2 and a nucleic acid molecule encoding the BV.

[0042] Preferably, the amino acid sequence of N1 is shown as SEQ ID NO.1, the amino acid sequence of N2 is shown as SEQ ID NO.3, and the amino acid sequence of BV is shown as SEQ ID NO.5.

[0043] Preferably, the nucleotide sequence of the nucleic acid molecule encoding the N1 is as shown in SEQ ID NO.2 or as shown in the completely complementary sequence shown in SEQ ID NO:2.

[0044] Preferably, the nucleotide sequence of the nucleic acid molecule encoding the N2 is as shown in SEQ ID NO.4 or as shown in the completely complementary sequence shown in SEQ ID NO:4.

[0045] Preferably, the nucleotide sequence of the nucleic acid molecule encoding the BV is as shown in SEQ ID NO.6 or the completely complementary sequence as shown in SEQ ID NO:6.

[0046] Preferably, in the antigen, the mass ratio of circular RNA1, circular RNA2 and circular RNA3 is (1-2): (1-2): (1-2).

[0047] More preferably, in the antigen, the mass ratio of circular RNA1, circular RNA2 and circular RNA3 is 1:1:1.

[0048] Preferably, the expression vectors of circular RNA1 to circular RNA3 use the PUC57-T4 vector as a backbone vector.

[0049] More preferably, an expression cassette is connected between the T7 promoter and the EcoRV restriction site of the PUC57-T4 vector, and the expression cassette comprises 3'Intron, E2, SPACER 2, IRES, NA molecule, SPACER 1, E1 and 5'Intron connected in sequence from 5'→3' direction, and the NA molecule is a nucleic acid molecule encoding the N1, a nucleic acid molecule encoding the N2 or a nucleic acid molecule encoding the BV.

[0050] Preferably, the antigen further comprises a drug delivery carrier. The drug delivery carrier includes but is not limited to cationic polymers, extracellular vesicles and lipid nanoparticles.

[0051] More preferably, the drug delivery vehicle comprises lipid nanoparticles.

[0052] Further preferably, the circular RNA composition is loaded into the lipid nanoparticles by microfluidics technology.

[0053] Further preferably, the lipid nanoparticles are obtained by fully reacting ionizable cationic lipids, cholesterol, distearoylphosphatidylcholine and 1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol 2000.

[0054] More preferably, the molar ratio of the ionizable cationic lipid, cholesterol, distearoylphosphatidylcholine and 1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol 2000 is (48-52):(8-12):(35-40):(1-2).

[0055] Still further preferably, the molar ratio of the ionizable cationic lipid, cholesterol, distearoylphosphatidylcholine and 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000 is 50:10:37.5:1.5.

[0056] More preferably, the encapsulation efficiency of the lipid nanoparticles for the circular RNA composition is 90% to 100%.

[0057] Still more preferably, the encapsulation rates of the lipid nanoparticles for the circular RNA1, circular RNA2 and circular RNA3 are 93% to 95%, 93% to 95% and 93% to 95%, respectively.

[0058] Most preferably, the encapsulation efficiency of the lipid nanoparticles for the circular RNA1, circular RNA2 and circular RNA3 is 93.52%, 94.65% and 93.74%, respectively.

[0059] Preferably, the influenza virus vaccine further comprises any one or more of a pharmaceutically acceptable adjuvant, carrier, diluent or excipient.

[0060] Compared with the prior art, the present invention has the following beneficial effects:

[0061] The present invention delivers neuraminidase of three influenza virus strains through circular RNA, and the prepared trivalent vaccine can induce the body to produce strong NA antibodies and T cell responses, has a broad-spectrum protective efficacy against both homologous and heterologous strains, induces high-level and broad-spectrum immune responses, and provides a new vaccination strategy for responding to seasonal influenza. BRIEF DESCRIPTION OF THE DRAWINGS

[0062] Figure 1 This is a map of the PCAGGS-Flag-N1 (H1N1) vector.

[0063] Figure 2 A is a map of the circular RNA expression vector containing NA and a schematic diagram of circular RNA synthesis; A is a map of the circular RNA expression vector containing N1 (T4-PIE-N1); B is a schematic diagram of the principle of synthesizing circular RNA based on T4-intron self-cleavage.

[0064] Figure 3 The electrophoresis results of circular RNA and linear RNA precursors; L: linear RNA precursor; L+R: linear RNA precursor digested with RNaseR; C: circularized RNA; C+R: circularized RNA digested with RNaseR.

[0065] Figure 4 The dynamic light scattering results of each LNPs are the light intensity-particle size distribution curves of N1 LNP, N2 LNP, BV LNP and blank LNP.

[0066] Figure 5Figure 1 is the ELISA test result of antibody titer in mouse serum before and after vaccination; A is the titer of immune serum against A / Michgan / 45 / 2015(H1N1)N1 protein of monovalent circular RNA vaccine Monovalent-N1; B is the titer of immune serum against A / Swizerland / 9715293 / 2013(H3N2)N2 protein of monovalent circular RNA vaccine Monovalent-N2; C is the titer of immune serum against A / Swizerland / 9715293 / 2013(H3N2)N2 protein of monovalent circular RNA vaccine Monovalent- BV immune serum against B / Colorado / 06 / 2017BV protein titer; D is the trivalent circular RNA vaccine immune serum against A / Michgan / 45 / 2015 (H1N1) N1 protein titer; E is the trivalent circular RNA vaccine immune serum against A / Swizerland / 9715293 / 2013 (H3N2) N2 protein titer; F is the trivalent circular RNA vaccine immune serum against B / Colorado / 08 / 2017BV protein titer.

[0067] Figure 6 Figure 2 is the ELLA test result of mouse serum NA inhibition ability (NAI) before and after vaccination; A is the NAI titer of monovalent circular RNA vaccine Monovalent-N1 immune serum against A / Michgan / 45 / 2015 (H1N1) N1 protein; B is the NAI titer of monovalent circular RNA vaccine Monovalent-N2 immune serum against A / Swizerland / 9715293 / 2013 (H3N2) N2 protein; C is the NAI titer of monovalent circular RNA vaccine Monovalent- BV immune serum against B / Colorado / 06 / 2017BV protein NAI titer; D is the NAI titer of trivalent circular RNA vaccine immune serum against A / Michgan / 45 / 2015 (H1N1) N1 protein; E is the NAI titer of trivalent circular RNA vaccine immune serum against A / Swizerland / 9715293 / 2013 (H3N2) N2 protein; F is the NAI titer of trivalent circular RNA vaccine immune serum against B / Colorado / 08 / 2017BV protein.

[0068] Figure 7To strengthen the test results of neutralizing antibody titers in mouse serum after immunization; A is the neutralization titer of monovalent circular RNA vaccine Monovalent-N1 immune serum against A / California / 04 / 2009 (H1N1); B is the neutralization titer of monovalent circular RNA vaccine Monovalent-N2 immune serum against A / Swizerland / 9715293 / 2013 (H3N2); C is the neutralization titer of monovalent circular RNA vaccine Monovalent-BV immune serum against B / Colorado / 06 / 2017; D is the neutralization titer of trivalent circular RNA vaccine immune serum against A / California / 04 / 2009 (H1N1); E is the neutralization titer of trivalent circular RNA vaccine immune serum against A / Swizerland / 9715293 / 2013 (H3N2); F is the neutralization titer of trivalent circular RNA vaccine immune serum against B / Colorado / 08 / 2017.

[0069] Figure 8 is the T cell response level of mice after vaccination; A is the ELISOPT detection of the level of IFN-γ and IL-4 secreting cells against N1 of mice after vaccination; B is the ELISOPT detection of the level of IFN-γ and IL-4 secreting cells against N2 of mice after vaccination; C is the ELISOPT detection of the level of IFN-γ and IL-4 secreting cells against BV NA of mice after vaccination; D is the representative well of IFN-γ ELISPOT; E is the representative well of IL-4 ELISPOT.

[0070] Fig. 9 This is a virus challenge experiment after mice were vaccinated with a trivalent circular RNA vaccine; a is the statistical results of the body weight and mortality of mice for 14 consecutive days after being challenged with 5×LD50 of A / HongKong / 8 / 1968 (H3N2) after mice were vaccinated with two doses (30μg and 6μg) of the trivalent circular RNA vaccine or a placebo (i.e., blank LNP) control; b is the statistical results of the body weight and mortality of mice for 14 consecutive days after being challenged with 5×LD50 of A / Puerto Rico / 8 / 1934 (H1N1) after the same vaccination program; c is the statistical results of the body weight and mortality of mice for 14 consecutive days after being challenged with 5×LD50 of B / Colorado / 06 / 2017 after the same vaccination program.

[0071] Fig.10The protective effects of monovalent and trivalent vaccines on mice are compared; a is the statistical results of body weight and mortality for 14 consecutive days after mice were vaccinated with monovalent circular RNA vaccine Monovalent-N1 (10μg or 2μg) or trivalent circular RNA vaccine (30μg or 6μg) and then challenged with 5×LD50 of A / California / 04 / 2009 (H1N1); b is the statistical results of body weight and mortality for 14 consecutive days after mice were vaccinated with monovalent circular RNA vaccine Monovalent-N2 (10μg or 2μg) or trivalent circular RNA vaccine (30μg or 6μg) and then challenged with 5×LD50 of A / Gui Zhou / 54 / 1989 (H3N2).

[0072] Fig.11 These are the HE staining results of lung sections of mice after vaccination following B / Malaysia / 2506 / 2004 virus infection; Blank is the placebo group; Trivalent is the trivalent circular RNA vaccine; Monovalent is the monovalent circular RNA vaccine Monovalent-BV.

[0073] Fig.12 Statistics of the binding breadth between immune sera and heterologous virus strain NA of mice after vaccination; A is the monovalent circular RNA vaccine Monovalent-N1; B is the monovalent circular RNA vaccine Monovalent-N2; C is the monovalent circular RNA vaccine Monovalent-BV; D is the trivalent circular RNA vaccine; CA09 is the A / California / 04 / 2009 (H1N1) strain; BWIS15 is the B / Wisconsin / 81 / 2015 strain; VN51 is the A / Viet Nam / 1203 / 2004 (H5N1) strain; BCOL17 is the B / Colorado / 08 / 2017 strain; BM18 is the A / Brevig Mission / 1 / 1918 (H1N1) strain; SL32 is A / Swizerland / 9715293 / 2013 (H3N2) strain; Mich15 is A / Michgan / 45 / 2015 (H1N1) strain; KA17 is A / Kansas / 14 / 2017 (H3N2) strain; JP22 is A / Janpan / 305 / 1957 (H2N2) strain; GZ89 is A / GuiZhou / 54 / 1989 (H3N2) strain; PHP32 is A / Philippines / 2 / 1982 (H3N2) strain. DETAILED DESCRIPTION

[0074] The present invention is further described in detail below in conjunction with the accompanying drawings and specific examples of the specification. The examples are only used to explain the present invention and are not used to limit the scope of the present invention. The test methods used in the following examples are conventional methods unless otherwise specified; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.

[0075] Example 1 Preparation of circular RNA

[0076] This example generates circular RNA through a replacement intron-exon (PIE) splicing strategy.

[0077] Referring to the construction method of “T4 PIE-Fluci” in the prior art CN118178350A, the PUC57-T4 vector was used as the backbone vector, and the NA (i.e., N1) (amino acid sequence as shown in SEQ ID NO.1, and the nucleotide sequence optimized by human codons as shown in SEQ ID NO.2) from influenza A / Michigan / 45 / 2015 (H1N1) strain A / Michigan / 45 / 2015 (H1N1) subtype influenza virus strain A / Switzerland / 9715293 / 2013 (H3N2) NA (i.e., N2) (amino acid sequence as shown in SEQ ID NO.3, and the nucleotide sequence optimized by human codons as shown in SEQ ID NO.4) and the NA (i.e., BV) (amino acid sequence as shown in SEQ ID NO.5, and the nucleotide sequence optimized by human codons as shown in SEQ ID NO.6) from influenza B subtype influenza virus strain B / Flordia / 12 / 2017 (Victoria) subtype influenza virus strain B / Vorica ... NO.6), inserted into the PUC57-T4 vector to obtain a circular RNA expression vector, namely the GR693-1-pUC57-cexu-T4PIE vector.

[0078] The GR693-1-pUC57-cexu-T4PIE vector has nucleotide sequences such as 3' intron (3'Intron), exon short fragment E2 (E2), spacer sequence 2 (SPACER 2), internal ribosome entry site (IRES), NA, spacer sequence 1 (SPACER 1), exon segment fragment 1 (E1) and 5' intron (5'Intron) connected in sequence from 5' to 3' direction between the T7 promoter and the EcoRV restriction site.

[0079] Table 1 Nucleotide sequences of the elements of GR693-1-pUC57-cexu-T4PIE vector

[0080]

[0081] Note: The circular RNA sequence generated by the PIE splicing strategy is the sequence shown in Table 1, after removing the Intron element and being transcribed into RNA.

[0082] (1) Obtaining NA fragments

[0083] N1 (SEQ ID NO.2), N2 (SEQ ID NO.4) and BV (SEQ ID NO.6) were respectively inserted between the EcoRΙ and XhoΙ restriction sites of the PCAGGS vector to obtain NA gene template vectors containing NA sequences, which were named PCAGGS-Flag-N1 (H1N1), PCAGGS-Flag-N2 (H3N2), and PCAGGS-Flag-BV (Victoria), respectively. The structure of PCAGGS-Flag-N1 (H1N1) is as follows: Figure 1 As shown, the difference between PCAGGS-Flag-N2 (H3N2) and PCAGGS-Flag-BV (Victoria) is that N1 in the vector is replaced by N2 or BV.

[0084] Using the above NA gene template vector as a template, primers were used to perform PCR amplification to obtain three NA fragments. The primers used for PCR are as follows:

[0085] Upstream primers for N1 and N2 (N1 / N2-F, the upstream primers used for N1 and N2 are the same):

[0086] BV upstream primer (BV-F):

[0087] Downstream primer of N1 (N1-R):

[0088] Downstream primer of N2 (N2-R):

[0089] BV downstream primer (BV-R):

[0090] In the above primers, the underlined part “ ” is the linker sequence for homologous recombination, and the boxed “□” part is the sequence complementary to N1 (SEQ ID NO.2), N2 (SEQ ID NO.4) or BV (SEQ ID NO.6).

[0091] The PCR reaction system was: 1 μL of upstream primer (10 μM), 1 μL of downstream primer (10 μM), 22 μL of H2O, 1 μL of NA gene template plasmid, and 25 μL of PCR mix. The PCR reaction program was: denaturation at 95°C for 2 min, 35 cycles (denaturation at 95°C for 1 min, annealing at 57°C for 1 min, and extension at 72°C for 90 s).

[0092] Afterwards, the PCR products were recovered by gel electrophoresis, namely, the N1 fragment (i.e., N1 with a linker sequence for homologous recombination (SEQ ID NO.2)), the N2 fragment (i.e., N2 with a linker sequence for homologous recombination (SEQ ID NO.4)) and the BV fragment (i.e., BV with a linker sequence for homologous recombination (SEQ ID NO.6)).

[0093] (2) Construction of circular RNA expression vector containing NA

[0094] The GR693-1-PUC57-cexu-T4PIE vector was double-digested with Bst XI and SalⅠ, and then the digestion product was obtained by nucleic acid electrophoresis and gel recovery, that is, the linearized GR693-1-PUC57-cexu-T4PIE vector was obtained.

[0095] The three NA fragments recovered by PCR in the previous step were homologously recombined with the enzyme-cut products respectively. The reaction system used was: 2×seamLess mix 7μL; linear GR693-1-PUC57-cexu-T4PIE vector 2.0μL; N1 fragment or N2 fragment or BV fragment, 0.4μL; water 4.6μL.

[0096] Incubate at 55°C for 30 minutes. After the end, transform into competent cells. Specifically, add the obtained reaction product to 50 μL T1 competent cells, place on ice for 30 minutes, heat shock at 42°C for 90 seconds, take it out and place it on ice for 2 minutes, add 600 μL LB culture medium without antibiotics, culture at 37°C, 220 rpm for 1 hour, centrifuge the bacterial solution at 3000 rpm for 2 minutes, remove the supernatant, keep 50 μL of pipetting and mixing, and spread the bacterial solution on the ampicillin resistance plate. Culture in a biochemical incubator at 37°C for 14 hours.

[0097] The colonies were selected for sequencing, and the colonies with correct sequencing were retained. The plasmids were extracted to obtain the circular RNA expression vectors of three NAs, which were named as: T4-PIE-N1, T4-PIE-N2 and T4-PIE-BV. The structure of T4-PIE-N1 is as follows: Figure 2 As shown in A in FIG, the difference between T4-PIE-N2 and T4-PIE-BV is that N1 in the vector is replaced by N2 or BV. Figure 2As shown in B, the circular RNA expression vector cuts off the intron sequences at both ends through type I intron self-splicing, and connects between E1 and E2 to form a circular RNA molecule connected end to end.

[0098] (3) In vitro transcription

[0099] T4-PIE-N1, T4-PIE-N2 and T4-PIE-BV were digested with EcoR V, and the digested products were recovered using a PCR product recovery kit to obtain linearized T4-PIE-N1, linearized T4-PIE-N2 and linearized T4-PIE-BV as in vitro transcription templates.

[0100] Linear precursor RNA was generated from three in vitro transcription templates using T7 RNA polymerase. The reaction system was: 10 μL T7 RNA polymerase, 20 μL 5× T7 polymerase buffer, 2 μg in vitro transcription template (linearized T4-PIE-N1, linearized T4-PIE-N2 or linearized T4-PIE-BV), 2 μL inorganic pyrophosphatase (0.1 U / μL), 2.5 μL RNase inhibitor (40 U / μL), and 10 μL NTP mix (20 mM). In vitro transcription conditions were: incubation at 37°C for 2 h. After completion, DNA in the obtained transcription product was digested with DNase I, and the transcription product was purified using an RNA purification kit (Magen Biotech) to obtain linear transcripts containing three NAs (N1, N2, and BV), i.e., linear RNA precursors.

[0101] (4) RNA cyclization and identification

[0102] Heat each linear RNA precursor to 70°C and incubate for 5 minutes; then immediately put it in ice; then add circularization buffer (5×, composition: 50mM Tris-HCl, 1mM DTT, 2mM GTP, 150mM NaCl, 20mM MgCl2, 2mM GTP); then heat the RNA to 55°C and incubate for 8min; then add 10μL of RNase R (40U / μL) and incubate at 37°C for 15min to degrade the uncircularized RNA; finally, purify the incubation product with an RNA purification kit to obtain circularized RNA, i.e., circular RNA. Store the circular RNA at -80°C.

[0103] The prepared circular RNA was identified by 1.5% agarose gel electrophoresis to determine its purity. Figure 3As shown, after RNase R digestion, the transcription product only contains circular RNA, which shows that the circular RNA prepared in this example has a high purity and can resist RNase R digestion. The above results show that the circular RNA expressing three kinds of NAs was successfully constructed, wherein the circular RNA expressing N1 (SEQ ID NO.1) was recorded as circRNA-N1, the circular RNA expressing NA2 (SEQ ID NO.3) was recorded as circRNA-N2, and the circular RNA expressing BV (SEQ ID NO.5) was recorded as circRNA-BV.

[0104] Example 2 Preparation of circular RNA vaccine

[0105] The present invention refers to the method of "preparing nanolipid particles encapsulating circular RNA" in the prior art CN118178350A, and uses microfluidic mixing to encapsulate the three circular RNAs (circRNA-N1, circRNA-N2 and circRNA-BV) prepared in Example 1 into lipid nanoparticles (LNPs) to prepare three monovalent circular RNA vaccines. The specific method is as follows:

[0106] In ethanol, an ionizable cationic lipid (Cas No.: 2089251-47-6), cholesterol, distearoylphosphatidylcholine (DSPC) and 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000 (DMG-PEG 2000) were thoroughly mixed at a molar ratio of 50:10:37.5:1.5 to form an organic phase.

[0107] The mass of each circular RNA was calculated based on the "nitrogen-phosphorus ratio (N / P) of 4", and each circular RNA was dissolved in 50 mM citric acid buffer (PH=4) to form an aqueous phase with a final concentration of 90 μg / ml.

[0108] The organic phase and the aqueous phase were mixed in a volume ratio of 1:3 through an iNanoE microfluidic device, with a total flow rate of 12 ml / min. After obtaining the mixed sample, it was immediately diluted 40 times with 1×PBS, and then the buffer was exchanged through a 100kd ultrafiltration tube to remove ethanol and concentrate LNPs. The ultrafiltration products obtained were LNPs encapsulating three circular RNAs (circRNA-N1, circRNA-N2, and circRNA-BV), which were respectively recorded as N1 LNP, N2 LNP, and BV LNP. The LNPs prepared using pure 50mM citric acid buffer (PH=4) as the aqueous phase were blank LNPs, recorded as blank LNP.

[0109] The content of each circular RNA in LNPs was quantitatively determined using Qubit HS RNA Kit (Thermo). In this example, the RNA content in N1 LNP was 411.6 ng / μL (encapsulation efficiency was 93.52%), the RNA content in N2 LNP was 452 ng / μL (encapsulation efficiency was 94.65%), and the RNA content in BV LNP was 537.2 ng / μL (encapsulation efficiency was 93.74%).

[0110] The particle size and dispersibility of LNPs were determined by dynamic light scattering. Figure 4 As shown, the size of LNPs is about 80nm, with good dispersion and uniformity. This indicates that three monovalent circular RNA vaccines were successfully constructed, the monovalent circular RNA vaccine encapsulating circRNA-N1 was recorded as Monovalent-N1, the monovalent circular RNA vaccine encapsulating circRNA-N2 was recorded as Monovalent-N2, and the monovalent circular RNA vaccine encapsulating circRNA-BV was recorded as Monovalent-BV.

[0111] The three monovalent vaccines were mixed in equal proportions of the mass of the encapsulated RNA (i.e., circRNA-N1:circRNA-N2:circRNA-BV=1:1:1) to prepare a trivalent circular RNA vaccine, denoted as Trivalent.

[0112] Example 3 Performance evaluation of circular RNA vaccines

[0113] 1. Experimental Methods

[0114] 1. Animal Immunization Experiment

[0115] (1) Vaccination

[0116] BALB / c mice (SPF grade, weight 20±3g, 6-8 weeks old female, n=5 / group) were used as experimental animals. The monovalent circular RNA vaccine and trivalent circular RNA vaccine prepared in Example 2 were diluted with PBS, and the dose was 30μg (i.e., 10μg of Monovalent-N1, 10μg of Monovalent-N2 and 10μg of Monovalent-BV) or 6μg (i.e., 2μg of Monovalent-N1, 2μg of Monovalent-N2 and 2μg of Monovalent-BV), and each mouse was inoculated by intramuscular injection of 100μL of PBS-diluted circular RNA vaccine, and a booster immunization was performed 28 days after immunization.

[0117] On the 21st and 49th day after vaccination, blood samples were collected from mice by submandibular vein puncture to prepare immune sera for serological tests such as ELISA, ELLA, and microneutralization experiments.

[0118] (2) Attack

[0119] Four weeks after booster immunization (i.e., day 56 after inoculation), mice were anesthetized and intranasally infected with 5×LD50 influenza virus (A / California / 04 / 2009 (H1N1) strain, B / Colorado / 06 / 2017 (Victoria) strain, A / Hong Kong / 8 / 1968 (H3N2) strain, A / Puerto Rico / 8 / 1934 (H1N1) strain, A / Gui Zhou / 54 / 1989 (H3N2) strain, or B / Malaysia / 2506 / 2004 strain).

[0120] The homologous virus strain used for infection was B / Colorado / 06 / 2017 (Victoria) strain.

[0121] Heterologous strains with different NA and vaccine sequences were selected for infection: A / California / 04 / 2009 (H1N1) strain, A / Hong Kong / 8 / 1968 (H3N2) strain, A / Puerto Rico / 8 / 1934 (H1N1) strain, A / GuiZhou / 54 / 1989 (H3N2) strain, and B / Malaysia / 2506 / 2004 strain.

[0122] The mice injected with blank LNPs served as the placebo control group (i.e., Blank).

[0123] The body weight of mice was monitored for 14 days after infection, and mice with a body weight loss greater than 25% were humanely euthanized.

[0124] 2. ELISA to detect antibody titer

[0125] Three neuraminidase recombinant proteins (recombinant NA proteins from A / Michigan / 45 / 2015N1, A / Swizerland / 9715293 / 2013N2 and B / Colorado / 08 / 2017BV strains prepared by the preparation method of "recombinant NA proteins" in the prior art "DOI:10.1016 / j.cell.2018.03.030") were diluted with PBS and coated on 96-well ELISA plates at 200 ng / well, respectively, overnight at 4°C. The next day, the plates were washed six times with PBS containing 0.05% Tween-20 (PBST), and then added to 150 μL of blocking solution (PBS containing 3% bovine serum albumin) and incubated at 37°C for 1 hour. After blocking, the mouse serum was diluted 3 times in PBS, added to the 96-well plate, incubated at 37°C for 2 hours, washed 6 times with PBST, and added with 1:4000 dilution of anti-mouse secondary antibody. After incubation at 37°C for 1 hour, the color developing solution was added for color development. The absorbance was measured at 405nm. The serum titer was defined as the serum dilution factor with an absorbance value exceeding 2 times the background well.

[0126] 3. Detection of NA inhibitory ability of mouse serum by enzyme-linked lectin reaction (ELLA)

[0127] Fetuin was diluted with PBS to obtain a coating solution with a concentration of 25 μg / ml. 100 μL of the coating solution was added to each well of a 96-well plate and coated at 4°C overnight. Mouse serum was serially diluted 2-fold in DPBS buffer (DPBS-T-BSA, containing 0.133 g / L CaCl2, 0.1 g / LMgCl2, 0.05% Tween-20 and 1% bovine serum albumin), and the diluted serum was mixed with a certain concentration (i.e., the protein concentration corresponding to 90% of the maximum enzyme activity of NA enzyme activity) of NA recombinant protein (refer to the recombinant NA protein from A / Michigan / 45 / 2015N1, A / Swizerland / 9715293 / 2013N2 and B / Colorado / 08 / 2017BV strains prepared by the preparation method of “recombinant NA proteins” in the prior art “DOI:10.1016 / j.cell.2018.03.030”) and incubated at 37°C for 2 hours. Then, it was added to a 96-well plate, incubated at 37°C for 18 hours, and then washed 6 times with PBST. Then, 100 μL of HRP-labeled peanut agglutinin was added to each well and incubated at room temperature for 2 h in the dark. The plate was then washed 9 times with PBST and a color developing solution was added. The absorbance at 405 nm was read. The inhibition rate of serum on NA at different dilutions was calculated (inhibition rate = (1-serum well reading / no serum well reading) * 100%), and the data were analyzed using PRISM software to draw an inhibition rate-serum dilution curve, and the dilution with a serum inhibition rate of 50% was used as the NA inhibition (NAI) titer of the serum.

[0128] 4. Microneutralization experiment to identify the neutralizing antibody titer of mouse serum

[0129] The serum obtained 21 days after booster immunization was treated with 3 volumes of receptor-destroying enzyme and inactivated at 56°C for 30 min to obtain inactivated serum.

[0130] MDCK cells were cultured at 2×10 4 The cells were inoculated at a density of 100 / well in a 96-well cell culture plate. On the second day of culture, the inactivated mouse serum was diluted 2-fold (i.e., the dilution was 10-5120) in the infection culture medium (DMEM+1% penicillin-streptomycin antibiotics+1μg / ml TPCK trypsin) to obtain a final volume of 60μL diluted serum. The diluted serum and an equal volume of 100TCID 50The mixture was mixed with influenza virus (A / California / 04 / 2009 (H1N1) strain, A / Switzerland / 9715293 / 2013 (H3N2) strain or B / Colorado / 06 / 2017 strain) and incubated at 37°C for 1 h to obtain a virus-serum mixture; the MDCK cells were washed twice with PBS, and 100 μL / well of the virus-serum mixture was added to a 96-well plate inoculated with MDCK cells and cultured at 37°C for 1 h; the MDCK cells were then washed twice with PBS, and 100 μL / well of the infection culture medium containing the same dilution of inactivated serum was added, and the culture was continued for 48 h.

[0131] After the culture, the replication of influenza virus in MDCK cells was detected by hemagglutination test, and the highest dilution of inactivated serum without virus detection was used as the neutralization titer.

[0132] 5. Elispot experiment to identify the level of mouse T cell response

[0133] On the 10th day after booster immunization, mice (5 mice / group) were killed, spleens were removed, and spleen cells were ground with a nylon mesh until a cell suspension containing single spleen cells was obtained.

[0134] Anti-Mouse IFN-γ antibody (manufacturer: U-CyTech, catalog number: CT655-10) or IL-4 antibody (manufacturer: U-CyTech, catalog number: CT657-10) was added to a 96-well ELISpot plate as a coating antibody, incubated at 4°C overnight, and then blocked with RPMI1640 culture medium containing 10% FBS at 37°C for 1 hour to obtain a coated ELISPOT plate.

[0135] The cell suspension of spleen cells was added to the coated ELISPOT plate, and then recombinant NA protein at a concentration of 10 μg / ml (refer to the preparation method of "recombinant NA proteins" in the prior art "DOI:10.1016 / j.cell.2018.03.030" for A / Michigan / 45 / 2015N1, A / Swizerland / 9715293 / 2013N2 and B / Colorado / 08 / 2017BV strains) was added and stimulated at 37°C, 5% CO2 for 40 hours; then the spleen cells were washed 6 times with PBST; a 1:100 diluted biotin-labeled anti-IFN-γ or IL-4 detection antibody was added, incubated at room temperature for 2 hours, and then incubated with 100 μL HRP-labeled streptavidin diluted 1:500 was incubated at room temperature for 1 h; finally, 5-bromo-4-chloro-3-indolyl-phosphate / nitro blue tetrazolium (BCIP / NBT) substrate solution was added, incubated for 5 min, and the plate was washed with pure water to detect the number of spots.

[0136] 6. HE staining to identify lung lesions in mice

[0137] Mice were killed four days after infection with 1×LD50 B / Malaysia / 2506 / 2004 virus, and their lungs were removed and fixed with 4% paraformaldehyde. The lung tissues were sent to Shenzhen Lingfu Top Biotechnology Co., Ltd. for slide preparation, HE staining and photography.

[0138] 7. ELISA to identify the binding breadth of NA of heterologous strains in mouse serum

[0139] 96-well ELISA plates were coated with NA antigens of heterologous strains (from strains A / California / 04 / 2009 (H1N1, CA09), A / Viet Nam / 1203 / 2004 (H5N1, VN51), A / Brevig Mission / 1 / 1918 (H1N1, BM18), A / Michgan / 45 / 2015 (H1N1, Mich15), A / Janpan / 305 / 1957 (H2N2, JP22), A / Philippines / 2 / 1982 (H3N2, PHP32), A / Gui Zhou / 54 / 1989 (H3N2, GZ89), A / Kansas / 14 / 2017 (H3N2, KA17), A / Swizerland / 9715293 / 2013 (H3N2, SL32), B / Colorado / 08 / 2017 (COL17) and B / Wisconsin / 81 / 2015 (WIS15) were detected according to the method in "2. ELISA detection of antibody titer" of this example.

[0140] 2. Experimental Results

[0141] 1. ELISA test results of antibody titer

[0142] like Figure 5 As shown in A to C, two doses (10 μg and 2 μg) of three monovalent circular RNA vaccines (Monovalent-N1, Monovalent-N2 and Monovalent-BV) all stimulated significant NA-specific antibody responses in mice, with higher titers in the high-dose group (10 μg), and antibody titers increased significantly after booster immunization. This indicates that the three monovalent circular RNA vaccines (Trivalent) have good immunogenicity and can induce high antibody titers through a prime-boost immunization strategy.

[0143] like Figure 5As shown in Figures D to F, the trivalent circular RNA vaccine induced antibody responses to N1, N2, and BV in mice, and the titers increased significantly after booster immunization, and the vaccine had no bias in antibody responses to the three NAs. This indicates that the three NA immunogens delivered simultaneously by circular RNA basically do not interfere with each other, and the preparation scheme of the trivalent circular RNA vaccine is effective and feasible.

[0144] 3. ELLA test results of mouse serum NA inhibitory ability

[0145] like Figure 6 As shown in A to C in the figure, the sera of mice vaccinated with two doses (10 μg and 2 μg) of three monovalent circular RNA vaccines (Monovalent-N1, Monovalent-N2 and Monovalent-BV) showed inhibitory effects on recombinant NA proteins from A / Michigan / 45 / 2015N1, A / Swizerland / 9715293 / 2013N2 and B / Colorado / 08 / 2017BV, respectively, and the NA inhibition titer increased significantly after booster immunization, indicating that the three monovalent circular RNA vaccines successfully induced NA inhibitory antibodies in mice. Figure 6 As shown in D to F, the immune serum of the trivalent circular RNA vaccine showed inhibitory titers to the three recombinant NA proteins. The monovalent circular RNA vaccine and the trivalent circular RNA vaccine prepared by the present invention can exert protective functions through NAI antibodies.

[0146] Previous studies have confirmed that NAI antibody titers are correlated with NA-mediated immune protection. The above results indicate that the monovalent circular RNA vaccine and trivalent circular RNA vaccine prepared by the present invention can exert a protective function through NAI antibodies.

[0147] 4. Results of mouse serum neutralization ability test

[0148] like Figure 7 As shown in A to C in Figure 1, the booster immune sera of mice vaccinated with two doses (10 μg and 2 μg) of three monovalent circular RNA vaccines (Monovalent-N1, Monovalent-N2 and Monovalent-BV) had significant inhibitory effects on A / California / 04 / 2009 (H1N1), A / Swizerland / 9715293 / 2013 (H3N2) and B / Colorado / 08 / 2017 viruses in vitro. Figure 7 As shown in Figures D to F, the trivalent circular RNA vaccine has an inhibitory effect on all three strains, indicating that the circular RNA NA vaccine can stimulate neutralizing antibodies and inhibit viral replication.

[0149] 5. Elispot test results of mouse T cell response level

[0150] like Figure 8 As shown in A to E in Figure 1, a large number of NA-specific IFN-γ and IL-4 secreting cells were detected in the spleen cells of mice vaccinated with three monovalent circular RNA vaccines (Monovalent-N1, Monovalent-N2, and Monovalent-BV), indicating that circular RNA vaccines stimulated a strong T cell response.

[0151] 6. Protective efficacy of trivalent circular RNA vaccine against heterologous strains

[0152] like Fig. 9 As shown in a, after infection with the A / Hong Kong / 8 / 1968 (H3N2) strain, the mice vaccinated with the trivalent circular RNA vaccine survived and showed less weight loss, while all the mice in the control group died.

[0153] like Fig. 9 As shown in b, after infection with the A / Puerto Rico / 8 / 1934 (H1N1) strain, mice vaccinated with the trivalent circular RNA vaccine experienced moderate weight loss, but all survived in the end, while all mice in the control group died.

[0154] like Fig. 9 As shown in c, after infection with the B / Colorado / 06 / 2017 (Victoria) strain, all mice vaccinated with the trivalent circular RNA vaccine survived without significant weight loss or disease.

[0155] The above results indicate that the trivalent circular RNA vaccine provided by the present invention has good protective efficacy against heterologous strains with a long genetic distance.

[0156] 7. Comparison of protective efficacy between monovalent circular RNA vaccine and trivalent circular RNA vaccine

[0157] like Fig.10 As shown in a, after infection with the A / Califoria / 04 / 2009 (H1N1) strain, mice vaccinated with the monovalent circular RNA vaccine (Monovalent-N1) and the trivalent circular RNA vaccine survived with only slight weight loss. Fig.10As shown in b, after infection with the A / Gui Zhou / 54 / 1989 (H3N2) strain, mice vaccinated with the monovalent circular RNA vaccine (Monovalent-N1) experienced severe weight loss and died (all mice in the 2μg group died, and 3 mice in the 10μg group died); while mice vaccinated with the trivalent circular RNA vaccine only experienced slight weight loss and both doses of immunized mice survived. This indicates that the cross-protection effect of the trivalent circular RNA vaccine is better than that of the monovalent vaccine for heterologous strains, indicating that the combination mode of the trivalent circular RNA vaccine of the present invention can stimulate a broader spectrum of immune protection.

[0158] like Fig.11 As shown, after B / Malaysia / 2506 / 2004 virus infection, the lung sections of mice vaccinated with the trivalent circular RNA vaccine showed minimal inflammatory cell infiltration and mild alveolar lesions, while the lung inflammatory cell infiltration and alveolar thickening of mice vaccinated with the monovalent circular RNA vaccine (Monovalent-N1) were more severe. This shows that the trivalent circular RNA vaccine of the present invention can more effectively prevent lung damage caused by influenza virus infection.

[0159] like Fig.12 As shown in A, the immune serum of mice vaccinated with the monovalent circular RNA vaccine (Monovalent-N1) can only bind to the NA proteins of four homologous and heterologous strains (A / California / 04 / 2009 (H1N1, CA09), A / Viet Nam / 1203 / 2004 (H5N1, VN51), A / Brevig Mission / 1 / 1918 (H1N1, BM18) and A / Michgan / 45 / 2015 (H1N1, Mich15)).

[0160] like Fig.12 As shown in B, the immune serum of mice vaccinated with the monovalent circular RNA vaccine Monovalent-N2 can only bind to the NA proteins of five homologous and heterologous strains (A / Janpan / 305 / 1957 (H2N2, JP22), A / Philippines / 2 / 1982 (H3N2, PHP32), A / Gui Zhou / 54 / 1989 (H3N2, GZ89), A / Kansas / 14 / 2017 (H3N2, KA17), and A / Swizerland / 9715293 / 2013 (H3N2, SL32)).

[0161] like Fig.12As shown in C, the immune serum of mice vaccinated with the monovalent circular RNA vaccine Monovalent-BV can only bind to two heterologous strains (B / Colorado / 08 / 2017 (COL17) and B / Wisconsin / 81 / 2015 (WIS15)).

[0162] like Fig.12 As shown in D, the immune serum of mice vaccinated with the trivalent circular RNA vaccine can bind to all 11 homologous and heterologous strains (A / California / 04 / 2009 (H1N1, CA09), A / Viet Nam / 1203 / 2004 (H5N1, VN51), A / Brevig Mission / 1 / 1918 (H1N1, BM18), A / Michgan / 45 / 2015 (H1N1, Mich15), A / Janpan / 305 / 1957 (H2N2, JP22), A / Philippines / 2 / 1982 (H3N2, PHP32), A / Gui Zhou / 54 / 1989(H3N2,GZ89), A / Kansas / 14 / 2017(H3N2,KA17), A / Swizerland / 9715293 / 2013(H3N2,SL32), B / Colorado / 08 / 2017(COL17) and B / Wisconsin / 81 / 2015(WIS15)), and the titer in the high-dose group was higher. This shows that the trivalent circular RNA vaccine can stimulate a broader spectrum of antibody responses.

[0163] The above results show that the protective efficacy of the trivalent circular RNA vaccine provided by the present invention is better than that of the monovalent vaccine and has better cross-protection efficacy.

[0164] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit the protection scope of the present invention. For ordinary technicians in this field, other different forms of changes or modifications can be made based on the above descriptions and ideas. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A circular RNA composition encoding neuraminidase, characterized in that: The neuraminidase includes three subtypes, namely N1, N2 and BV; wherein the amino acid sequence of N1 has at least 95% identity with SEQ ID NO.1, the amino acid sequence of N2 has at least 95% identity with SEQ ID NO.3, and the amino acid sequence of BV has at least 95% identity with SEQ ID NO.5; The circular RNA composition comprises circular RNA1 to circular RNA3, wherein the circular RNA1 to circular RNA3 respectively comprise a nucleic acid molecule encoding the N1, a nucleic acid molecule encoding the N2, and a nucleic acid molecule encoding the BV.

2. The circular RNA composition according to claim 1, characterized in that The mass ratio of the circular RNA 1, circular RNA 2 and circular RNA 3 is (1-2): (1-2): (1-2).

3. The circular RNA composition according to claim 2, characterized in that The mass ratio of circular RNA1, circular RNA2 and circular RNA3 is 1:1:

1.

4. The circular RNA composition according to claim 1, characterized in that The expression vectors of the circular RNA1 to circular RNA3 use the PUC57-T4 vector as a backbone vector.

5. The circular RNA composition according to claim 4, characterized in that An expression cassette is connected between the T7 promoter and the EcoRV restriction site of the PUC57-T4 vector, and the expression cassette comprises 3'Intron, E2, SPACER 2, IRES, NA molecule, SPACER 1, E1 and 5'Intron connected in sequence from 5'→3' direction, and the NA molecule is a nucleic acid molecule encoding the N1, a nucleic acid molecule encoding the N2 or a nucleic acid molecule encoding the BV.

6. Use of the circular RNA composition according to any one of claims 1 to 5 in the preparation of an anti-influenza virus product.

7. The use according to claim 6, characterized in that: The influenza virus is a seasonal influenza virus, including H1N1, H3N2 and influenza B viruses.

8. An antigen for preparing an influenza virus vaccine, characterized in that: A circular RNA composition comprising any one of claims 1 to 5.

9. Use of the antigen according to claim 8 in the preparation of influenza virus vaccines.

10. An influenza virus vaccine, characterized in that: Comprising the antigen according to claim 8.